Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Withdrawn × 3-Iodobenzylguanidine × NET × Clear all

Phase

Status

Completed 4 Withdrawn 1 Unknown 1 Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

NET 1 Endocrine 1 CNS 1

Conditions

Neuroendocrine Tumors 1

Interventions

telotristat ethyl 3 lutetium Lu 177 dotatate 2 177Lu-octreotide, DOTA(0)-Tyr(3)- 2 veliparib 1 pasireotide 1 gallium Ga 68 dotatate 1 Tretinoin 1 Temozolomide 1 Isotretinoin 1 Introns 1 Everolimus 1 Diazoxide 1 Capecitabine 1 3-Iodobenzylguanidine 1 177Lu-octreotate 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04831567 2022-05-19

MIBNET

AC Camargo Cancer Center

Phase 2 Withdrawn

Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon ⚡